These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32616595)
21. Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung? Mirimanoff RO Chin Clin Oncol; 2015 Dec; 4(4):42. PubMed ID: 26730754 [TBL] [Abstract][Full Text] [Related]
22. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919 [TBL] [Abstract][Full Text] [Related]
23. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce. Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110 [TBL] [Abstract][Full Text] [Related]
24. A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). Teke ME; Sarvestani AL; Hernandez JM; Fernando HC; Timmerman RD Ann Surg Oncol; 2022 Aug; 29(8):4686-4687. PubMed ID: 35524087 [No Abstract] [Full Text] [Related]
25. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal? Gulstene S; Ruwanpura T; Palma D; Joseph N Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):733-740. PubMed ID: 36050221 [TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750 [TBL] [Abstract][Full Text] [Related]
27. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135 [TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Stereotactic Ablative Radiotherapy for All Stages of Non-Small Cell Lung Cancer; Definitive versus Consolidative. Kim H; Kim SM; Yang DS; Lee KH; Kim YB Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143981 [No Abstract] [Full Text] [Related]
30. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360 [TBL] [Abstract][Full Text] [Related]
31. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121 [TBL] [Abstract][Full Text] [Related]
33. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma. McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479 [TBL] [Abstract][Full Text] [Related]
34. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks KN Pilot Feasibility Stud; 2016; 2():55. PubMed ID: 27976752 [TBL] [Abstract][Full Text] [Related]
35. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639 [TBL] [Abstract][Full Text] [Related]
36. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort. Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546 [TBL] [Abstract][Full Text] [Related]
37. Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. Chen H; Louie AV; Boldt RG; Rodrigues GB; Palma DA; Senan S Clin Lung Cancer; 2016 Sep; 17(5):e141-e149. PubMed ID: 26791542 [TBL] [Abstract][Full Text] [Related]